Innovative Screening Device for Early Detection of Retinal Ischemia in Diabetics

University of Pittsburgh researchers have developed a novel screening device for detecting retinal ischemia in diabetics. This device aims to address the limitations of current screening methods by providing a quantitative, objective measure of retinal ischemia using a non-invasive, non-mydriatic approach. The device could revolutionize the screening process for diabetic retinopathy, making it more efficient and accessible in primary care settings.

The fig is a block diagram of one particular embodiment of an apparatus for screening for retinopathy.

Description

The screening device uses pupillography to measure the eye’s response to light, providing a quantitative assessment of retinal ischemia. It features a dual light source: one that illuminates the central retina and another that illuminates the midperipheral retina. The device measures the pupil’s response to these light sources, with a built-in computer controlling the light sources and recording the responses. The ratio of the light intensities provides a measure of midperipheral retinal sensitivity, indicating the presence of ischemia.

Applications

- Screening of diabetics in primary care settings for diabetic retinopathy
- Prospective treatment trials to prevent proliferative diabetic retinopathy
- Screening patients with sickle-cell retinopathy

Advantages

This device provides a quantitative, objective measurement of retinal ischemia, works in over 90% of the diabetic population requiring screening, and is relatively insensitive to small refractive errors. The procedure is non-invasive, non-mydriatic, and requires minimal patient cooperation. It is simple to operate, provides immediate results, and can be used in a wide range of clinical settings. Additionally, it is relatively inexpensive to manufacture and can be internally calibrated for sequential measurements over time.

Invention Readiness

The device is currently in the concept phase, with the design phase being relatively simple due to the adaptation of pre-existing technology. The device will require validation in human subjects with diabetes and varying severity of diabetic retinopathy. Threshold values for referral will need to be empirically determined and tested. Clinical trials and IDE certification will be required for commercialization.

IP Status

https://patents.google.com/patent/US7258444B2